9.64
+1.15%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sedana Medical AB (publ)
Its shares trade on Nasdaq Stockholm under the ticker SEDANA.ST. It has been listed since 21 June 2017. In the fiscal year to 31 December 2025, it reported revenue of SEK 200.2m and a net loss of SEK 59.2m. At that date it held total assets of SEK 954.5m and shareholders' equity of SEK 900.8m.
Sedana Medical AB is a medical technology company, which engages in the development, manufacture, and sale of medical devices and drug development for future projects around AnaConDa. The company is headquartered in Danderyd, Stockholm. The company went IPO on 2017-06-21. The company develops, markets and sales medical devices and conducts drug development for future projects around AnaConDa technology. The AnaConDa technology delivery enables of volatile anaesthetics to invasively ventilated patients. The products portfolio comprises disposable medical devices AnaConDa for administration of volatile anaesthetics, AnaConDa syringes, FlurAbsorb charcoal filters for removing halogenated hydrocarbon anaesthetic gases, different lines and connectors which can be used to connect the FlurAbsorb filter, adaptors, among others. The Company’s main shareholders are board members, Linc AB and Magiola Consulting AB.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 21 Jun 2017
- Employees
- 46
- Website
- sedanamedical.com ↗
Leadership
Pay as last reported
- Mr. Claus BjerreIndependent Chairman of the BoardSEK 762,000
- Mr. Johannes DollPresident, Chief Executive OfficerSEK 6.6m
- Mr. Johan SpetzChief Financial Officer
- Ms. Jessica WestfalVice President - Regulatory Affairs and QA
- Ms. Karolina VilvalGeneral Counsel
- Mr. Uwe VeismannGeneral Manager, Germany
- Mr. Stefan KrischSupply Chain and Manufacturing Director
- Mr. Peter SackeyChief Medical Officer
- Mrs. Hilde FurbergIndependent DirectorSEK 270,000
- Ms. Donna HaireIndependent DirectorSEK 167,000
- Mr. Christoffer RosenbladIndependent DirectorSEK 325,000
- Dr. Jens ViebkeIndependent DirectorSEK 167,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 53
- Environment
- 65
- Social
- 51
- Governance
- 43
- Direct emissions (scope 1)
- 228.3 t
- Energy emissions (scope 2)
- 12 t
- Value chain emissions (scope 3)
- 1,129 t
- Women in the workforce
- 63.30275%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sedana Medical AB develops AnaConDa technology for volatile anaesthetics delivery to ventilated patients.
- AnaConDa syringes and FlurAbsorb filters are key products in their medical device portfolio.
- Sedana Medical AB has a strong focus on drug development for future projects around AnaConDa technology.
Weaknesses
- Sedana Medical AB has only 46 full-time employees as of the latest data.
- The company's main shareholders include board members, Linc AB, and Magiola Consulting AB.
- Sedana Medical AB's business is limited to the Health Care sector with no diversification.
Opportunities
- Sedana Medical AB can expand its product portfolio with new medical devices for anaesthesia delivery.
- The global Health Care sector offers growth potential for medical technology companies like Sedana Medical AB.
- AnaConDa technology has potential for international market expansion beyond current regions.
Threats
- Sedana Medical AB faces competition from established medical device manufacturers in the Health Care sector.
- Regulatory changes in the Health Care industry could impact Sedana Medical AB's product approvals.
- The company's reliance on a single technology, AnaConDa, poses a risk if it fails to gain market acceptance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.